Earlybird Venture Capital

What they fund

• Pre-Seed & Seed — Initial ticket sizes up to €12m, targeting 20% Pre-Seed and 60% Seed allocations [1], - Series A — 20% of allocations, backing companies like Aleph Alpha and Isar Aerospace [1][3], - Healthcare — €173m (£148m) fund dedicated to digital health, diagnostics, medical devices, and biopharma [2], - University Spin-offs — €75m UNI-X fund targeting pre-seed and early seed deep tech innovations from European universities [5]

Investment thesis

Earlybird Venture Capital powers Europe’s tech innovators with financial resources, strategic support, and access to a vast international network, aiming to empower early-stage entrepreneurs to build impactful, lasting companies [1]. The firm positions itself as a "Day 1 Partner" that goes "all in" supporting founders from idea to IPO, emphasizing genuine interaction and deep market understanding [2]. They focus on backing groundbreaking technologies to create meaningful, lasting impact, leveraging a team of independent thinkers who have backed and built exceptional companies [1]. Earlybird backs Pre-Seed to Series A founders in emerging tech – from fintech to nuclear fusion [1]. They live and breathe tech, aiming to partner with founders before the breakthrough [1].

Credibility: Earlybird homepage [1], UiPath and Aleph Alpha founder testimonials [1].

Value add

Earlybird positions itself as a "Day 1 Partner" that goes "all in" supporting founders from idea to IPO [1]. They provide strategic support, customer introductions, and Series A connections [1]. The firm leverages a vast international network and a team of independent thinkers who have backed and built exceptional companies [1]. They emphasize genuine interaction and deep market understanding [2].

Fit verdict: Earlybird is a strong fit for founders seeking a long-term partner who will actively support them from pre-seed through IPO, particularly in deep tech, AI, and healthcare.

Founder diligence script:

• What specific strategic support and customer introductions can you provide at the pre-seed stage?
• How does your UNI-X fund network of professors and spotters help commercialize university spin-offs?
• Can you share examples of how your international network has helped portfolio companies expand globally?

Portfolio focus

• Software & AI — UiPath, Aleph Alpha, Celus, Arago, Bayshore, QuantumDiamonds [1][3], - Fintech & Insurtech — N26, Upvest, smava, ottonova, FintechOS, Certivity [1][4][3], - Deep Tech & Aerospace — Isar Aerospace, Marvel Fusion, Involve Space, ORiS, QuantumDiamonds [1][3], - Healthcare & Biotech — HAYA Therapeutics, ImCheck Therapeutics, Portal Biotech, Priothera, Hilo [3]

Notable investments & exits

• UiPath — IPO in 2021, Earlybird backed the company from early stages [1], - N26 — Valued at €9B in 2021, Earlybird was a key early investor [1], - smava — Became Germany’s leading consumer finance platform, backed by Earlybird [1], - Snyk — UK-founded cybersecurity unicorn, backed by Earlybird [2]

Strategic implications

Earlybird's €2.5B AUM and 168 portfolio companies indicate a mature, well-capitalized firm with a strong track record in European tech. Their focus on pre-seed to Series A, particularly in deep tech and healthcare, positions them as a key player in Europe's innovation ecosystem. The UNI-X fund's focus on university spin-offs addresses a critical gap in the European deep tech commercialization pipeline, potentially giving Earlybird access to high-potential, early-stage deals. Earlybird's active deployment and strong reserve posture suggest they are well-positioned to capitalize on future market opportunities, particularly in AI and healthcare.

Where they could go further

Earlybird could expand its geographic focus beyond Europe, particularly into the US and Asia, to access larger markets and talent pools., The firm could increase its focus on climate tech and sustainability, which are increasingly important to LPs and founders., Earlybird could enhance its post-investment support by offering more structured mentorship and operational resources to portfolio companies., The firm could explore co-investment opportunities with other VCs to share risk and leverage complementary expertise.